| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | FLT; FLT-1; VEGFR1; VEGFR-1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human FLT1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于FLT1抗体的3篇代表性文献的简要信息(注：以下文献为示例性虚构，仅供参考格式)：
1. **文献名称**：*Targeting FLT1 with a novel monoclonal antibody inhibits angiogenesis and tumor growth in solid tumors*
**作者**：Smith A, et al.
**摘要**：该研究开发了一种针对FLT1/VEGFR1的新型单克隆抗体，通过阻断VEGF信号通路抑制肿瘤血管生成，在动物模型中显著减少肿瘤体积并降低转移风险。
2. **文献名称**：*FLT1-specific antibody reduces placental inflammation in preeclampsia models*
**作者**：Chen L, et al.
**摘要**：探讨FLT1抗体在子痫前期治疗中的作用，发现其通过中和可溶性FLT1(sFLT1)缓解胎盘血管异常和炎症反应，为妊娠相关疾病的治疗提供新策略。
3. **文献名称**：*Structural basis of FLT1 recognition by a therapeutic antibody for age-related macular degeneration*
**作者**：Yamamoto K, et al.
**摘要**：通过冷冻电镜解析FLT1抗原-抗体复合物结构，阐明抗体结合表位及抑制VEGF信号传导的分子机制，为优化抗体药物治疗眼部新生血管疾病奠定基础。
如需真实文献，建议在PubMed或Web of Science中以“FLT1 antibody”或“anti-FLT1 therapy”为关键词检索近年研究。
The FMS-like tyrosine kinase 1 (FLT1), also known as vascular endothelial growth factor receptor 1 (VEGFR1), is a transmembrane receptor tyrosine kinase primarily involved in angiogenesis and vascular development. It binds ligands such as VEGF-A, VEGF-B, and placental growth factor (PlGF), regulating endothelial cell proliferation, migration, and survival. FLT1 plays dual roles: its membrane-bound form mediates signal transduction, while a soluble isoform (sFLT1) acts as a decoy receptor to modulate ligand availability. Dysregulation of FLT1 signaling is linked to pathological conditions, including cancer, diabetic retinopathy, and preeclampsia.
FLT1 antibodies are essential tools for studying these processes. Monoclonal or polyclonal antibodies targeting specific FLT1 epitopes are used in research applications like Western blotting, immunohistochemistry (IHC), and flow cytometry to quantify receptor expression, localization, and activation. Therapeutic FLT1-blocking antibodies have been explored to inhibit angiogenesis in cancers or ocular diseases by disrupting VEGF/FLT1 interactions. Conversely, agonistic antibodies or sFLT1-based therapies (e.g., aflibercept) aim to neutralize excess VEGF in conditions like age-related macular degeneration.
Despite its lower kinase activity compared to VEGFR2 (KDR), FLT1's unique ligand-binding profile and regulatory functions make it a critical target for both mechanistic studies and clinical interventions. Antibodies against FLT1 continue to advance our understanding of vascular biology and therapeutic strategies for angiogenesis-related diseases.
×
